Drug Profile
ASP 2408
Alternative Names: ASP-2408Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Maxygen
- Developer Astellas Pharma
- Class Antirheumatics; Immunoglobulin fusion proteins
- Mechanism of Action CD28 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 01 Nov 2013 Discontinued - Phase-I for Rheumatoid arthritis in Japan (SC)
- 01 Nov 2013 Discontinued - Phase-I for Rheumatoid arthritis in USA (IV)
- 01 Oct 2013 Astellas Pharma completes a phase I trial in Healthy volunteers in Japan (NCT02140125)